AS-298 VARC Outcomes Following Transcatheter Aortic Valve Implantation With Both Edwards SAPIEN™ And Medtronic CoreValve ReValving System® Devices: Results from the Milan Registry

Results: In total, 347 patients were included in this analysis. The majority of cases used the transfemoral access site (n=283; 81.6%). The overall mean age was 79.5±7.0 years, logistic EuroSCORE 23.7±16.7% and STS-PROM score 8.9±8.7%. The median clinical follow-up length was 350 (IQR 81-461) days. Thirty-day mortality was 4.9% in the whole study population with myocardial infarction rate 1.4% and stroke 0.9%. Life-threatening bleeding occurred in 24.3% and 14.5% had a major vascular complication. At one-year, all-cause mortality was 19.6%. Analysis according to valve type in the transfemoral population revealed no differences in combined safety or combined eficacy endpoints. However, there was a signiicantly higher rate of device success amongst the ESV group (96.0% vs. 89.0%; p=0.022) with additionally a signiicantly higher rate of conduction disturbances/arrhythmia (28.4% vs. 13.2%; p=0.002) as well as pacemaker implantation (25.7% vs. 5.7%; p<0.001) with MCV compared with ESV.